Literature DB >> 1698823

Tartrate resistant acid phosphatase positive splenic lymphoma: a relatively benign condition occurring in a time-space cluster?

P Kettle1, T C Morris, G M Markey, H D Alexander, R C Curry, D Hayes, C H Cameron, P G Toner.   

Abstract

Conventional light and electron microscopic studies, together with cytochemical and immunocytochemical staining procedures, were carried out to ascertain whether the lymphomata of four elderly female patients living within 10 kilometers of each other, who presented within a short space of time with massive splenomegaly and varying cytopenia, belonged to any particular subgroup of lymphoma. In each case the lymphoma had a diffuse pattern and mature B cell phenotype. The malignant cells were of uniform cell type, slightly larger than admixed polymorphonuclear leucocytes, and showed minimal nuclear irregularity and positivity for tartrate resistant acid phosphatase (TRAP) staining. Their clinical and morphological features were compared with those of other lymphoproliferative disorders, but while sharing some features in common with each condition, this small group of patients seemed to have a unique combination of findings. The cytopenias of all four responded well after removal of the spleen and their disease has not been aggressive. It is concluded that these patients have a distinct subgroup of lymphoma, which it is important to recognise so that inappropriate use of aggressive cytotoxic drugs can be avoided.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698823      PMCID: PMC502747          DOI: 10.1136/jcp.43.9.714

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

Review 1.  Malignant lymphomas: current classification and new observations.

Authors:  R C Braylan; E S Jaffe; C W Berard
Journal:  Pathol Annu       Date:  1975

2.  Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  J Clin Pathol       Date:  1989-06       Impact factor: 3.411

3.  Malignant lymphoma diagnosed at splenectomy and idiopathic splenomegaly. A clinicopathologic comparison.

Authors:  J C Long; A C Aisenberg
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

4.  Lymphosarcoma of the spleen. Results of diagnostic splenectomy in 11 patients.

Authors:  A T Skarin; F R Davey; W C Moloney
Journal:  Arch Intern Med       Date:  1971-02

5.  Recommended methods for cytological procedures in haematology. International Committee for Standardization in Haematology (ICSH).

Authors:  A Shibata; J M Bennett; G L Castoldi; D Catovsky; G Flandrin; E S Jaffe; I Katayama; K Nanba; F Schmalzl; L T Yam
Journal:  Clin Lab Haematol       Date:  1985

6.  Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens.

Authors:  J V Melo; U Hegde; A Parreira; I Thompson; I A Lampert; D Catovsky
Journal:  J Clin Pathol       Date:  1987-06       Impact factor: 3.411

7.  The non-Hodgkin's lymphomas. I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969.

Authors:  D J Straus; D A Filippa; P H Lieberman; B Koziner; H T Thaler; B D Clarkson
Journal:  Cancer       Date:  1983-01-01       Impact factor: 6.860

8.  APAAP labelling of blood and bone-marrow samples for phenotyping leukaemia.

Authors:  W N Erber; L C Mynheer; D Y Mason
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

9.  Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases.

Authors:  D D Weisenburger; B N Nathwani; L W Diamond; C D Winberg; H Rappaport
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860

10.  Morphological and isoenzymatic differentiation of B-chronic lymphocytic leukaemia cells induced by phorbolester.

Authors:  H G Drexler; M Klein; N Bhoopalam; G Gaedicke; J Minowada
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.